Alternative chemoradiotherapy in anal carcinoma patients with mutations in thymidylate synthase and dihydropyrimidine dehydrogenase genes.

ABSTRACT:

Background

5-fluorouracil (5-FU) and mitomycin-C (MMC) with radiotherapy (RT) remain an established treatment for patients with anal cancer (AC). Genetic mutations in two major metabolizing enzymes for 5-FU; dihydropyrimidine dehydrogenase (DPYD and thymidylate synthetase (TYMS), have been associated with clinical response and toxicity. However, their place in the treatment of AC remains undetermined.

Methods

We retrospectively reviewed 21 patients with AC, including T2-4, N0-1, M0 or T1-4, N2-3, and M0 treated between 2012 and 2018. All patients were treated with 5-FU 1,000 mg/m²/day via continuous intravenous (IV) infusion 1-4 and 29-32, MMC 10 mg/m² IV bolus days 1 and 29 plus RT. Patients who developed ⩾3 grade toxicities were tested f

SUBMITTER: Saif MWM 

PROVIDER: S-EPMC8255561 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature